Disrupted mucosal barrier in quiescent ulcerative colitis: Effect of metronidazole and of a symbiotic preparation in a pilot cross-over study

Chinese Journal of Digestive Diseases

Volumn 4, Issue 4, 2003, Pages 180-185

  Marotta, F ^a   Naito, Y ^b   Tajiri, H ^c   Lighthouse, J ^b   Yoshioka, M ^b   Ogliari, C ^a   Bozzani, A ^a   Fuji, H ^d   Fesce, E ^a  

^a S Giuseppe Hospital   (Italy)

^b Immunology Research Institute and Clinic   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Osato Research Institute   (Japan)

Author keywords

Endotoxinemia; Metronidazole; Probiotics; SCM III; Ulcerative colitis

Indexed keywords

COLONY STIMULATING FACTOR 1; ENDOTOXIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESALAZINE; METRONIDAZOLE; PROBIOTIC AGENT;

ADULT; ARTICLE; BIFIDOBACTERIUM; BLOOD CHEMISTRY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON MUCOSA; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; ENTERITIS; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS HELVETICUS; MAINTENANCE THERAPY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0346966869     PISSN: 14439611     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1443-9573.2003.t01-4-.x     Document Type: Article

References (41)

1. Prytz H, Holst-Christensen J, Korner B, Liehr H. Portal venous and systemic endotoxinemia in patients without liver disease and systemic endotoxinemia in patients with cirrhosis. Scand J Gastroenterol 1976; 11: 857-63.
2. Zlysaszyk JC, Moon RJ. Fate of 51-Cr-labeled lipopolysaccharide in tissue culture cells and livers of normal mice. Infect Immun 1976; 14: 100-5.
3. Ruiter DJ, Van der Meulen J, Brouwer A. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 1981; 45: 38-45.
4. Monajemi H, Meenan J, Lamping R et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability increased protein. Gastroenterology 1996; 110: 733-9.
5. Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ. Endotoxin and bacteria in portal blood. Gastroenterology 1977; 72: 1268-70.
6. Aoki K. A study of endotoxemia in ulcerative colitis and Crohn's disease. I: Clinical study. Acta Med Okayama 1978; 32: 147-58.
7. Gardiner KR, Halliday MI, Barclay GR et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901.
8. Liao W, Lindgren S, Lindhagen T, Starck M, Floren CH. Plasma endotoxin in patients with quiescent Crohn's disease. J Int Med 1992; 232: 371.
9. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
10. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-4.
11. Gupta P. Is lactobacillus GG helpful in children with Crohn's disease: Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453-7.
12. Hartley MG, Hudson MJ, Hill MJ. The rectal mucosa-associated microflora in ulcerative colitis. J Med Microbiol 1990; 31: V-VI.
13. Fernandes CF, Shahani KM, Amer MA. Therapeutic role of dietary lactobacilli and lactobacillic fermented dairy products. FEMS Microbiol Rev 1987; 46: 343-56.
14. Lidbeck A, Geltner Allinger U, Orrhage KM. Impact of Lactobacillus acidophilus supplements on the fecal microflora and soluble faecal bile acids in colon cancer patients. Microb Ecol Health Dis 1991; 4: 81-8.
15. Marteau P, Pochart P, Flourié B. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of colonic flora in humans. Am J Clin Nutr 1990; 52: 685-8.
16. Barreto P, Naito Y, Marotta F et al. Gut flora manipulation mitigates ethanol-induced liver damage and endotoxinemia: experimental comparison between a novel probiotic and metronidazole. Intern Med J 2000; 7: 121-8.
17. Barreto R, Marotta F, Naito Y et al. Enhancement of interferon production and phagocytic function in aged rats by an enriched probiotic mixture. J Food Sci Nutr Suppl 1998; 3: S31-7.
18. Marotta F, Naito Y, Minelli E et al. Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study. Hepatogastroenterology 2003; (in press).
19. Fukui H, Brauner B, Bode JCh, Bode Ch. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 5: 162-9.
20. Bode C, Fukui H, Bode JCh. 'Hidden' endotoxin in plasma of patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 1993; 5: 247-62.
21. Fukui H, Tsujita S, Matsumoto M et al. Endotoxin inactivating of plasma in patients with liver cirrhosis. Liver 1995; 15: 104-9.
22. Hanamura T, Motoyoshi K, Yoshida K. Quantitation and identification of human monocyte colony-stimulating factor in human serum by enzyme-linked immunosorbent assay. Blood 1988; 72: 886-92.
23. Shadle PJ, Allen JI, Geier MD, Koths K. Detection of endogenous macrophage colony-stimulating factor (M-CSF) in human blood. Exp Hematol 1989; 17: 154-9.
24. Itoh Y, Okanoue T, Enjyo F. Macrophage colony stimulating factor and hepatitis. Int Hepatol Commun 1993; 1: 1-4.
25. Fabia R, Ar'Rajab A, Johansson ML et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993; 54: 248-55.
26. Fuller R. Probiotics in human medicine. Gut 1991; 32: 439-42.
27. Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Micr Ecol Health Dis 1989; 2: 131-6.
28. Gilliland SE, Speck ML. Antagonistic action of Lactobacillus acidophilus toward intestinal and food-borne pathogens in associative cultures. J Food Prot 1977; 40: 820-3.
29. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102: 488-95.
30. MacPherson A, Khoo UY, Forgacs I, Philpott I, Bjarnson J. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-75.
31. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium and antigens from resident intestinal flora in humans. Gut 1999; 44: 812-18.
32. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996; 110: 1395-403.
33. Wells CL, van de Westerlo EMA, Jechorek RP, Feltis BA, Wilkins TD, Erlandsen SL. Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalisation by HT-29 enterocytes. Gastroenterology 1996; 110: 1429-37.
34. Schumann RR, Leong SP, Flaggs GW et al. Structure and function of lypopolysaccharide binding protein. Science (Washington DC) 1990; 290: 1429-31.
35. Wells CL, Maddaus MA, Reynolds CM, Jechorek RP, Simmons RL. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 1987; 55: 2689-94.
36. Anderson BM, Solberg O. The endotoxin-liberating effect of antibiotics in vitro. Acta Pathol Microbiol Immunol Scand 1980; 88: 231-6.
37. Itoh Y, Okanoue T, Enjyo F et al. Serum levels of macrophage colony stimulating factor in liver disease. J Hepatol 1994; 21: 527-35.
38. Wang JM, Griffin JD, Rambaldi A et al. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol 1988; 141: 575-9.
39. Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Kashima K. The effect of prednisolone and interferons on serum macrophage colony stimulating factor concentrations in chronic hepatitis B. J Hepatol 1997; 26: 244-52.
40. Caradonna L, Amati L, Lella P, Jirilli E, Cascavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies and plasma endotoxin in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1495-502.
41. Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol 2002; 37 (Suppl. XIV): 73-77.